secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2024-11-29T23:59:59+00:00
Accession:  0001178913-24-003866
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics completes 1-for-9 reverse stock split, adjusts warrant terms
--------------------------------------------------------------------------------

- Reverse share split ratio 1-for-9 effective after market close on Nov 27, 2024; trading begins split-adjusted Nov 29, 2024.
- Authorized share capital remains $20,000, now 22,222,222 ordinary shares; par value increased from $0.0001 to $0.0009 per share.
- Each pre-split warrant now exercisable for 1/9th of a share at $103.50 per post-split share; no fractional shares (rounded up).
- Trading symbols unchanged: SLXN and SLXNW; new CUSIP for ordinary shares: G1281K 122.
- Fractional shares from warrant exercise rounded up to nearest whole number, requiring full exercise price payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/0001178913-24-003866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/zk2432408.htm
  HTML page:      https://secwatch.observer/filing/0001178913-24-003866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer